SEC Form 4 · accession 0001104659-15-065569
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — VP & Chief Scientific Officer
Period of report
Sep 15, 2015
Accepted (ET)
Sep 16, 2015 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2015 | M | 11,485 | $3.88 | A | 89,685 | D | |
| Common Stock | Sep 15, 2015 | S | 33,000 | $35.00 | D | 56,685 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $3.88 | Sep 15, 2015 | M | 11,485 | D | — | Dec 2, 2020 | Common Stock | 11,485 | 13,515 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.